

Richard B Warren

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3793200/richard-b-warren-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

228
papers

7,184
citations

44
h-index

77
g-index

260
ext. papers

8,972
ext. citations

5.1
avg. IF

6.09
L-index

#	Paper	IF	Citations
228	Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.. <i>Dermatology and Therapy</i> , 2022 , 12, 561	4	1
227	Clinical Disease Measures in Generalized Pustular Psoriasis.. <i>American Journal of Clinical Dermatology</i> , 2022 , 23, 39	7.1	1
226	Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey.. <i>British Journal of Dermatology</i> , 2022 ,	4	1
225	Remote consultations: an audit of the management of dermatology patients on biologics during the first wave of the COVID-19 pandemic.. <i>Journal of Dermatological Treatment</i> , 2022 , 1	2.8	
224	A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17.. <i>Dermatology and Therapy</i> , 2022 , 12, 787	4	0
223	Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.. <i>Advances in Therapy</i> , 2022 , 1	4.1	2
222	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. <i>Efficacy and Mechanism Evaluation</i> , 2022 , 9, 1-106	1.7	
221	Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 ,	4.6	3
220	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021 , 4, e2129639	10.4	17
219	Psoriasis and Comorbidities 2021 , 363-397		
218	DIFFERENCES IN CLINICAL FEATURES AND COMORBID BURDEN BETWEEN HLA-C*06:02 CARRIER GROUPS IN MORE THAN 9,000 PEOPLE WITH PSORIASIS. <i>Journal of Investigative Dermatology</i> , 2021	4.3	0
217	Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models. <i>Scientific Reports</i> , 2021 , 11, 23335	4.9	2
216	Tolérance et données d'efficacité complémentaires du bimekizumab chez des patients atteints de rhumatisme psoriasique : résultats 3 ans actualisés d'une étude d'extension en ouvert de phase IIb. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021 , 88, A186-A187	0.1	
215	Assessing the Quality and Coherence of Network Meta-Analyses of Biologics in Plaque Psoriasis: What Does All This Evidence Synthesis Tell Us?. <i>Dermatology and Therapy</i> , 2021 , 11, 181-220	4	3
214	Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. <i>British Journal of Dermatology</i> , 2021 , 185, 80-90	4	17
213	POS1022 BIMEKIZUMAB SAFETY AND EFFICACY IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM A PHASE 2b OPEN-LABEL EXTENSION STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 779-780	2.4	1
212	POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 795-1-796	2.4	8

211	Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single-centre cross-sectional study. <i>British Journal of Dermatology</i> , 2021 , 185, 441-443	4	5
210	Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). <i>British Journal of Dermatology</i> , 2021 , 185, 323-334	4	15
209	Defining trajectories of response in patients with psoriasis treated with biologic therapies. <i>British Journal of Dermatology</i> , 2021 , 185, 825-835	4	1
208	Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease. <i>British Journal of Dermatology</i> , 2021 , 185, 646-648	4	13
207	Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BE VIVID and BE READY Phase 3 Trials. <i>Dermatology and Therapy</i> , 2021 , 11, 1551-1569	4	1
206	Bimekizumab versus Adalimumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021 , 385, 130-141	4.2	28
205	Risk of hospitalization and death due to infection in people with psoriasis: a population-based cohort study using the Clinical Practice Research Datalink. <i>British Journal of Dermatology</i> , 2021 , 184, 78-86	4	16
204	Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies. <i>British Journal of Dermatology</i> , 2021 , 184, 640-651	4	9
203	Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. <i>British Journal of Dermatology</i> , 2021 , 184, 50-59	4	50
202	An evaluation of dermatology patients shielding during the COVID-19 outbreak. <i>Clinical and Experimental Dermatology</i> , 2021 , 46, 193-194	1.8	3
201	Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 824-834	4.6	18
200	Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). <i>British Journal of Dermatology</i> , 2021 , 184, 652-662	4	7
199	Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 450-457	4.6	7
198	Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 919-927	4.6	9
197	Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 60-71	11.5	77
196	Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre. <i>Dermatology and Therapy</i> , 2021 , 11, 149-160	4	7
195	Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1269-1277	4.5	18
194	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , 2021 , 397, 487-498	40	51

193	Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35 Suppl 1, 35-41	4.6	4
192	Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values 1, 2, 3 or 5 derived from a statistical conversion method. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1161-1175	4.6	3
191	Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2034-2044	4.6	2
190	Bimekizumab versus Secukinumab in Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2021 , 385, 142-152	5.2	38
189	Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics. <i>Dermatology and Therapy</i> , 2021 , 11, 1657-1665	4	0
188	Chromatin Looping Links Target Genes with Genetic Risk Loci for Dermatological Traits. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 1975-1984	4.3	6
187	Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 1872-1878	4.3	0
186	Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e636-e640	4.6	3
185	Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 1073-1081	5.1	2
184	Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2398-2408	4.6	1
183	Enhanced NF- κ B signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. <i>Nature Communications</i> , 2021 , 12, 4741	17.4	1
182	Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT). <i>British Journal of Dermatology</i> , 2021 ,	4	6
181	Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial. <i>Advances in Therapy</i> , 2021 , 38, 5253-5269	4.1	0
180	Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. <i>JAMA Dermatology</i> , 2021 , 157, 66-73	5.1	5
179	Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-analysis. <i>JAMA Dermatology</i> , 2020 , 156, 787-794	5.1	19
178	Mapping DNA interaction landscapes in psoriasis susceptibility loci highlights KLF4 as a target gene in 9q31. <i>BMC Biology</i> , 2020 , 18, 47	7.3	8
177	Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID-19 pandemic. <i>British Journal of Dermatology</i> , 2020 , 183, 792-794	4	32
176	Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). <i>British Journal of Dermatology</i> , 2020 , 183, 294-302	4	44

175	Progress to Date in Advancing Stratified Medicine in Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 619-626	7.1	5
174	The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1695-1706	4.6	29
173	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020 , 395, 427-440	4.0	65
172	Ixekizumab for the treatment of psoriasis: up-to-date. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 549-557	5.4	10
171	Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. <i>Clinical and Translational Science</i> , 2020 , 13, 400-409	4.9	5
170	Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1440-1448	4.6	15
169	Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. <i>British Journal of Dermatology</i> , 2020 , 183, 404-406	4	16
168	How is safety of dermatology drugs assessed: trials, registries, and spontaneous reporting. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 449-457	4.1	3
167	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 2129-2137	4.3	4
166	A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. <i>Trials</i> , 2020 , 21, 158	2.8	5
165	Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses. <i>Dermatology and Therapy</i> , 2020 , 10, 73-86	4	21
164	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. <i>Quality of Life Research</i> , 2020 , 29, 369-380	3.7	0
163	Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1138-1149	4.5	25
162	Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1161-1173	4.6	13
161	Risankizumab vs. adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal. <i>British Journal of Dermatology</i> , 2020 , 183, 220-221	4	1
160	PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis. <i>Advances in Therapy</i> , 2020 , 37, 4730-4753	4.1	2
159	Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. <i>American Journal of Human Genetics</i> , 2020 , 107, 539-543	11	16
158	Update on risankizumab for the treatment of moderate to severe psoriasis. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1245-1251	5.4	2

157	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. <i>JAMA Dermatology</i> , 2020 , 156, 1216-1222	5.1	5
156	Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis. <i>Dermatology and Therapy</i> , 2020 , 10, 1255-1272	4	4
155	Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. <i>British Journal of Dermatology</i> , 2020 , 182, 605-617	4	59
154	Secukinumab for patients failing previous tumour necrosis factor- α inhibitor therapy: results of a randomized open-label study (SIGNATURE). <i>British Journal of Dermatology</i> , 2020 , 183, 60-70	4	11
153	Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 769-778	4.6	18
152	Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). <i>British Journal of Dermatology</i> , 2020 , 182, 1158-1166	4	39
151	Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. <i>JAMA Dermatology</i> , 2019 , 155, 1235-1243	5.1	14
150	Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 699-709	7.1	4
149	Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1676-1684	4.6	39
148	Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, e352-e353	4.6	2
147	The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature. <i>Dermatology and Therapy</i> , 2019 , 9, 373-381	4	2
146	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. <i>British Journal of Dermatology</i> , 2019 , 181, 1265-1274		10
145	Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways. <i>British Journal of Dermatology</i> , 2019 , 181, 859-862	4	4
144	Long-term, real-world efficacy of biologics for psoriasis: a single centre's experience. <i>British Journal of Dermatology</i> , 2019 , 181, 599-601	4	2
143	Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>British Journal of Dermatology</i> , 2019 , 180, 329-337	4	24
142	Clinical and genetic differences between pustular psoriasis subtypes. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 1021-1026	11.5	80
141	Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. <i>PLoS ONE</i> , 2019 , 14, e0220868	3.7	81
140	Brodalumab in psoriasis: evidence to date and clinical potential. <i>Drugs in Context</i> , 2019 , 8, 212570	5.2	33

139	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 143, 2120-2130	11.5	63
138	OP0108 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAIVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY 2019 ,		4
137	Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2019 , 180, 76-85	4	15
136	Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. <i>British Journal of Dermatology</i> , 2019 , 180, 1069-1076	4	38
135	Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 115-123	4.3	32
134	Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. <i>British Journal of Dermatology</i> , 2019 , 180, 894-901	4	6
133	Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. <i>British Journal of Dermatology</i> , 2019 , 181, 256-264	4	9
132	A Framework for Multi-Omic Prediction of Treatment Response to Biologic Therapy for Psoriasis. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 100-107	4.3	18
131	Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. <i>British Journal of Dermatology</i> , 2018 , 178, 1064-1071 ⁴		30
130	Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1530-1534	4.6	11
129	Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2018 , 138, 775-784	4.3	46
128	Genotypic variability-based genome-wide association study identifies non-additive loci HLA-C and IL12B for psoriasis. <i>Journal of Human Genetics</i> , 2018 , 63, 289-296	4.3	5
127	Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. <i>JAMA Dermatology</i> , 2018 , 154, 581-588	5.1	46
126	Guselkumab for psoriasis: a critical appraisal of Phase III studies. <i>Immunotherapy</i> , 2018 , 10, 67-75	3.8	4
125	Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2018 , 138, 534-541	4.3	51
124	Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. <i>British Journal of Dermatology</i> , 2018 , 179, 1205-1207	4	50
123	Patient perceptions of clear/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 2200-2207	4.6	22
122	Ustekinumab for the treatment of psoriasis: an evidence update. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018 , 37, 143-147	1.4	6

121	Impact of Disease Severity, Illness Beliefs, and Coping Strategies on Outcomes in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2018 , 70, 295-302	4.7	16
120	Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32 Suppl 3, 3-14	4.6	41
119	A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. <i>Trials</i> , 2018 , 19, 465	2.8	11
118	What's new in psoriasis treatment? An analysis of systematic reviews published in 2015. <i>Clinical and Experimental Dermatology</i> , 2018 , 43, 759-765	1.8	2
117	Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 2178-2184	4.6	3
116	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study. <i>American Journal of Clinical Dermatology</i> , 2017 , 18, 405-411	7.1	16
115	Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2017 , 177, 879-881	4	19
114	Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 1646-1654	4.3	91
113	British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. <i>British Journal of Dermatology</i> , 2017 , 177, 628-636	4	158
112	Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1867-1875	4.6	9
111	Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. <i>British Journal of Dermatology</i> , 2017 , 177, 1410-1421	4	19
110	Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1487-1493	4.6	42
109	Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. <i>British Journal of Dermatology</i> , 2017 , 177, 828-836	4	15
108	A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). <i>British Journal of Dermatology</i> , 2017 , 177, 197-205	4	29
107	Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 441-448.e2	4.5	72
106	The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 243-249	5.9	4
105	An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017 , 389, 528-537	4.0	62
104	Reply to 'Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials': reply from the authors. <i>British Journal of Dermatology</i> , 2017 , 177, 1766-1767	4	1

103	Research Techniques Made Simple: Bioinformatics for Genome-Scale Biology. <i>Journal of Investigative Dermatology</i> , 2017 , 137, e163-e168	4.3	8
102	Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1774-1779	2.4	36
101	Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 2644-2646	4.3	7
100	Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 642-648	6.1	1
99	Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. <i>British Journal of Dermatology</i> , 2017 , 176, 890-901	4	79
98	Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>British Journal of Dermatology</i> , 2017 , 176, 1297-1307	4	37
97	Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. <i>Human Molecular Genetics</i> , 2017 , 26, 4301-4313 ²⁵	5.6	25
96	AB0727 Increased Rates of Hypertension in Patients with Psoriatic Arthritis Compared To Psoriasis Alone: Results from The UK Biobank. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1153.1-1153	2.4	1
95	Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. <i>Drug Safety</i> , 2016 , 39, 755-62	5.1	78
94	A novel mutation in IL36RN underpins childhood pustular dermatosis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 302-5	4.6	9
93	Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis. <i>Archives of Dermatological Research</i> , 2016 , 308, 201-5	3.3	29
92	One SNP at a Time: Moving beyond GWAS in Psoriasis. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 567-573	4.3	30
91	A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. <i>Dermatology and Therapy</i> , 2016 , 6, 1-12	4	92
90	Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. <i>British Journal of Dermatology</i> , 2016 , 175, 487-92	4	83
89	Novel Oral Therapies for Psoriasis and Psoriatic Arthritis. <i>American Journal of Clinical Dermatology</i> , 2016 , 17, 191-200	7.1	23
88	Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 1584-1591	4.3	49
87	British Association of Dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. <i>British Journal of Dermatology</i> , 2016 , 175, 23-44	4	52
86	Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation. <i>British Journal of Dermatology</i> , 2016 , 175, 1038-1044	4	28

85	The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 86-91	4.6	12
84	Effectiveness of Subcutaneous Methotrexate in Chronic Plaque Psoriasis. <i>Journal of Drugs in Dermatology</i> , 2016 , 15, 345-9	2.2	4
83	Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 1156-63	4.6	19
82	Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. <i>Journal of Dermatological Treatment</i> , 2015 , 26, 329-34	2.8	8
81	Efficacy and safety of emerging immunotherapies in psoriasis. <i>Immunotherapy</i> , 2015 , 7, 119-33	3.8	15
80	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , 2015 , 385 Suppl 1, S48 ⁴⁰	4.0	12
79	Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2011-9	9.5	69
78	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , 2015 , 6, 6046	17.4	103
77	Pharmacogenomics and the resulting impact on psoriasis therapies. <i>Dermatologic Clinics</i> , 2015 , 33, 149-60	4.2	8
76	Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions. <i>British Journal of Dermatology</i> , 2015 , 172, 933-9	4	12
75	Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. <i>British Journal of Dermatology</i> , 2015 , 173, 510-8	4	67
74	Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). <i>Journal of Investigative Dermatology</i> , 2015 , 135, 2632-2640	4.3	262
73	Treating moderate to severe psoriasis - best use of biologics. <i>Expert Review of Clinical Immunology</i> , 2014 , 10, 269-79	5.1	23
72	A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 438-53	4.6	100
71	The spectrum of oculocutaneous disease: Part I. Infectious, inflammatory, and genetic causes of oculocutaneous disease. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 795.e1-25	4.5	14
70	The spectrum of oculocutaneous disease: Part II. Neoplastic and drug-related causes of oculocutaneous disease. <i>Journal of the American Academy of Dermatology</i> , 2014 , 70, 821.e1-19	4.5	7
69	SAT0052 Influence of Immunogenicity and Drug Levels on the Efficacy of Long-Term Treatment of Rheumatoid Arthritis with Adalimumab and Etanercept: A Uk-Based Prospective Study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 608.1-608	2.4	5
68	Polymorphisms in IL-1B distinguish between psoriasis of early and late onset. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 1459-1462	4.3	19

67	Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis. <i>British Journal of Dermatology</i> , 2014 , 170, 206-9	4	7
66	Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools. <i>Arthritis Care and Research</i> , 2014 , 66, 1410-6	4.7	18
65	Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors. <i>British Journal of Dermatology</i> , 2014 , 170, 995-6	4	
64	Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. <i>British Journal of Dermatology</i> , 2014 , 171, 485-91	4	28
63	A case of CD8+ small/medium-sized pleomorphic T-cell lymphoma: clinical and histopathological differential diagnosis. <i>British Journal of Dermatology</i> , 2014 , 170, 204-6	4	4
62	Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1750-2	2.4	21
61	The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. <i>Rheumatology</i> , 2014 , 53, 213-22	3.9	137
60	Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis. <i>Journal of Dermatological Treatment</i> , 2014 , 25, 61-2	2.8	1
59	Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis--a multinational cross-sectional study. <i>Archives of Dermatological Research</i> , 2013 , 305, 899-907	3.3	37
58	National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines. <i>Archives of Dermatological Research</i> , 2013 , 305, 637-43	3.3	7
57	Expression of microRNA-184 in keratinocytes represses argonaute 2. <i>Journal of Cellular Physiology</i> , 2013 , 228, 2314-23	7	29
56	Dermatology: future therapeutic perspectives. <i>Dermatology and Therapy</i> , 2013 , 3, 115-6	4	
55	Psoriasis and susceptibility to other autoimmune diseases: an outline for the clinician. <i>Expert Review of Clinical Immunology</i> , 2013 , 9, 99-101	5.1	7
54	An investigation of rheumatoid arthritis loci in patients with early-onset psoriasis validates association of the REL gene. <i>British Journal of Dermatology</i> , 2013 , 168, 864-6	4	10
53	Ustekinumab for psoriatic arthritis: close to the PSUMMIT?. <i>Lancet, The</i> , 2013 , 382, 748-9	4.0	1
52	Cutaneous Mycobacterium haemophilum infection in a patient receiving infliximab for psoriasis. <i>British Journal of Dermatology</i> , 2013 , 168, 446-7	4	5
51	Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). <i>British Journal of Dermatology</i> , 2013 , 168, 802-7	4	103
50	Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 2340-2346	4.3	172

49	Patients' narratives. <i>Current Problems in Dermatology</i> , 2013 , 44, 145-57		1
48	In search of oral psoriasis. <i>Archives of Dermatological Research</i> , 2012 , 304, 1-5	3.3	26
47	Emerging therapies for the treatment of psoriasis. <i>Dermatology and Therapy</i> , 2012 , 2, 16	4	9
46	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , 2012 , 44, 1341-8	36.3	681
45	Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. <i>British Journal of Dermatology</i> , 2012 , 166, 189-95	4	30
44	Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. <i>British Journal of Dermatology</i> , 2012 , 166, 474-82	4	48
43	The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. <i>British Journal of Dermatology</i> , 2012 , 166, 545-54	4	81
42	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1350-4	2.4	31
41	A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. <i>British Journal of Dermatology</i> , 2011 , 164, 660-4	4	20
40	Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. <i>British Journal of Dermatology</i> , 2011 , 164 Suppl 1, 1-14	4	81
39	Psoriasis comorbidities: a worldwide problem?. <i>British Journal of Dermatology</i> , 2011 , 165, 929	4	
38	What's new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010. <i>Clinical and Experimental Dermatology</i> , 2011 , 36, 585-9; quiz 588-9	1.8	7
37	Re. major life-changing decisions and cumulative life course impairment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 246-246	4.6	4
36	Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 758-64	4.6	61
35	Letter from the editors. <i>Dermatology and Therapy</i> , 2011 , 1, 1	4	
34	Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1016-9	2.4	60
33	Ustekinumab for the treatment of psoriasis. <i>Expert Review of Clinical Immunology</i> , 2011 , 7, 155-64	5.1	8
32	Psoriatic arthritis--what the dermatologist needs to know. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 1270-7	4.6	16

31	Psoriasis: is the impairment to a patient's life cumulative?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 989-1004	4.6	127
30	Systemic therapies containing ethanol and gelatine excipients. <i>British Journal of Dermatology</i> , 2010 , 163, 885-6	4	
29	Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. <i>British Journal of Dermatology</i> , 2010 , 163, 859-62	4	19
28	What's new in psoriasis? Analysis of the clinical significance of new guidelines and systematic reviews on psoriasis published in 2008 and 2009. <i>Clinical and Experimental Dermatology</i> , 2010 , 35, 688-91; quiz 692	1.8	5
27	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. <i>Nature Genetics</i> , 2010 , 42, 985-90	36.3	773
26	The use of ustekinumab in autoimmune disease. <i>Expert Opinion on Biological Therapy</i> , 2010 , 10, 587-604	5.4	37
25	The future of biological therapies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010 , 29, 63-6	1.4	18
24	The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. <i>Molecular Diagnosis and Therapy</i> , 2010 , 14, 81-93	4.5	28
23	Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. <i>British Journal of Dermatology</i> , 2009 , 160, 162-9	4	43
22	Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. <i>British Journal of Dermatology</i> , 2009 , 160, 438-41	4	55
21	Recall injection-site reactions to etanercept in a patient with psoriasis. <i>Clinical and Experimental Dermatology</i> , 2009 , 34, 414-5	1.8	3
20	Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate. <i>Clinical and Experimental Dermatology</i> , 2009 , 34, 415-6	1.8	15
19	What's new in psoriasis? Analysis of the clinical significance of systematic reviews on psoriasis published in 2007 and 2008. <i>Clinical and Experimental Dermatology</i> , 2009 , 34, 664-7	1.8	7
18	Future therapeutic directions for the treatment of psoriasis. <i>Actas Dermo-sifiliográficas</i> , 2009 , 100 Suppl 2, 28-31	0.5	1
17	Genetic susceptibility to psoriasis: an emerging picture. <i>Genome Medicine</i> , 2009 , 1, 72	14.4	12
16	Adalimumab for the treatment of psoriasis. <i>Expert Review of Dermatology</i> , 2009 , 4, 15-21		1
15	No association between polymorphisms in the interleukin-15 gene and early-onset psoriasis in a UK cohort suggests heterogeneity for this susceptibility locus identified in Chinese psoriasis patients. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 2904-5	4.3	5
14	Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 1925-9	4.3	88

13	Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort. <i>Journal of Investigative Dermatology</i> , 2008 , 128, 1325-7	4.3	66
12	Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. <i>British Journal of Dermatology</i> , 2008 , 158, 962-8	4	33
11	Methotrexate for psoriasis in the era of biological therapy. <i>Clinical and Experimental Dermatology</i> , 2008 , 33, 551-4	1.8	48
10	Topical treatments for scalp psoriasis. <i>Drugs</i> , 2008 , 68, 2293-302	12.1	9
9	Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. <i>Clinics in Dermatology</i> , 2008 , 26, 438-47	3	59
8	Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene. <i>Human Molecular Genetics</i> , 2008 , 17, 1938-45	5.6	151
7	Identity of single-nucleotide polymorphisms used in a clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy: comment on the article by Wessels et al. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1204-5; author reply 1205		
6	Precalcaneal congenital fibrolipomatous hamartoma. <i>Pediatric Dermatology</i> , 2007 , 24, 74-5	1.9	14
5	A case of recalcitrant necrobiosis lipoidica responding to combined immunosuppression therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007 , 21, 830-1	4.6	7
4	Etanercept-induced dermatitis in a patient with rheumatoid arthritis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2006 , 20, 614-5	4.6	7
3	Porokeratotic eccrine ostial and dermal duct nevus. <i>Pediatric Dermatology</i> , 2006 , 23, 465-6	1.9	13
2	The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. <i>British Journal of Dermatology</i> , 2005 , 153, 869-73	4	21
1	An active chromatin interactome in relevant cell lines elucidates biological mechanisms at genetic risk loci for dermatological traits		1